Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer
Authors:
- Daniel C. ManevalDMDaniel C. Maneval
- Patricia MenzelPMPatricia Menzel
- Matthew P. HarrisMHMatthew P. Harris
- Suganto SutjiptoSSSuganto Sutjipto
- Mei-Ting VaillancourtMVMei-Ting Vaillancourt
- Whei-Mei HuangWHWhei-Mei Huang
- Duane E. JohnsonDJDuane E. Johnson
- Scott C. AndersonSAScott C. Anderson
- Shu Fen WenSWShu Fen Wen
- Robert BooksteinRBRobert Bookstein
- H. Michael ShepardHSH. Michael Shepard
- 1 September 1994
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 5 (9) , 1079-1088
Abstract
We have constructed recombinant human adenoviruses that express wild-type human p53 under the control of either the Ad 2 major late promoter (MLP) or the human cytomegalovirus (CMV) immediate early gene promoter. Each construct replaces the Ad 5 E1a and E1b coding sequences necessary for viral replication with the p53 cDNA and MLP or CMV promoter. These p53/Ad recombinants are able to express p53 protein in a dose-dependent manner in infected human cancer cells. Tumor suppressor activity of the expressed p53 protein was assayed by several methods. [3H]Thymidine incorporation assays showed that the recombinant adenoviruses were capable of inhibiting DNA synthesis in a p53-specific, dose-dependent fashion. Ex vivo treatment of Saos-2 tumor cells, followed by injection of the treated cells into nude mice, led to complete tumor suppression using the MLP/p53 recombinant. Following a single injection of CMV/p53 recombinant adenovirus into the peritumoral space surrounding an in vivo established tumor derived from a human small cell lung carcinoma cell line (NIH-H69), we were able to detect p53 mRNA in the tumors at 2 and 7 days post-injection. Continued treatment of established H69 tumors with MLP/p53 recombinant led to reduced tumor growth and increased survival time compared to control treated animals. These results indicate that recombinant adenoviruses expressing wild-type p53 may be useful vectors for gene therapy of human cancer. Introduction of the p53 tumor suppressor gene into tumors bearing p53 mutations can inhibit cellular proliferation and tumorigenicity. Wills et al. describe replication-deficient recombinant adenoviruses directing expression of human p53 both in vitro and in vivo. They show that adenovirus-mediated expression of wild-type p53 in p53 altered tumors can suppress proliferation and inhibit tumorigenicity in ex vivo and in vivo cancer models.Keywords
This publication has 29 references indexed in Scilit:
- Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic FibrosisHuman Gene Therapy, 1993
- p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell linesCarcinogenesis, 1993
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993
- Perspectives in Gene Therapy with Recombinat AdenovirusesExperimental and Clinical Endocrinology & Diabetes, 1993
- p53, guardian of the genomeNature, 1992
- In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epitheliumCell, 1992
- p53 Mutations in Human CancersScience, 1991
- Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6Nature, 1991
- Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infectionCell, 1982
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977